Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mild cognitive impairment as a diagnostic entity.

R C Petersen1

  • 1Department of Neurology, Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN, USA.

Journal of Internal Medicine
|August 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donanemab: Appropriate use recommendations.

The journal of prevention of Alzheimer's disease·2025
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease.

The journal of prevention of Alzheimer's disease..·2024
Same author

A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.

The journal of prevention of Alzheimer's disease·2024
Same author

Lecanemab: Appropriate Use Recommendations.

The journal of prevention of Alzheimer's disease·2023
Same author

Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites.

The journal of prevention of Alzheimer's disease·2022

Mild cognitive impairment (MCI) signifies an early stage of abnormal cognitive decline. Research shows MCI predicts faster progression to dementia and Alzheimer's disease (AD), aiding targeted therapeutic development.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is recognized as a transitional state between normal aging and dementia.
  • MCI research is extensive, with epidemiological studies confirming accelerated progression to dementia and Alzheimer's disease (AD).
  • Existing definitions and clinical implementation of MCI remain subjects of debate.

Purpose of the Study:

  • To clarify the definition and diagnostic criteria for MCI.
  • To propose subtypes of MCI, including prodromal dementia forms.
  • To present a diagnostic algorithm for MCI identification and subclassification.

Main Methods:

  • Review of existing literature on MCI.
  • Analysis of epidemiological data on MCI progression.

Related Experiment Videos

  • Development of a clinical diagnostic algorithm for MCI.

    • Main Results:

    • MCI is a valid predictor of progression to dementia and Alzheimer's disease.
    • Certain predictor variables for MCI progression have been identified.
    • Proposed MCI subtypes aim to encompass prodromal stages of various dementias.

    Conclusions:

    • Refined MCI criteria can improve diagnostic accuracy.
    • A standardized diagnostic algorithm can aid clinicians in identifying and classifying MCI.
    • Improved MCI characterization is crucial for designing targeted clinical trials and therapeutic interventions for neurodegenerative diseases.